Vaccines and Vaccine Adjuvants as Biological Response Modifiers

Infectious Disease Clinics of North America

Volumn 25, Issue 4, 2011, Pages 755-772

  Speil, Cristian ^a   Rzepka, Robert ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokines; Immunomodulatory drugs; Vaccine adjuvants

Indexed keywords

B7 ANTIGEN; BCG VACCINE; BIOLOGICAL RESPONSE MODIFIER; DENDRITIC CELL VACCINE; DNA VACCINE; GAMMA INTERFERON; GLATIRAMER; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON BETA SERINE; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 2; IPILIMUMAB; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MITOMYCIN C; MUCIN 1; OFLOXACIN; PEPTIDE VACCINE; PLACEBO; PROSTVAC; PROVENGE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TIPLIMOTIDE; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS LIKE PARTICLE VACCINE;

ADVANCED CANCER; ALLERGIC ENCEPHALOMYELITIS; ASTHENIA; BCG VACCINATION; BLADDER CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CHILL; CYSTITIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG USE; DYSPNEA; FEVER; HEADACHE; HEMATURIA; HUMAN; HYPERTENSION; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOMODULATION; INFECTION; LYMPHOMA; MELANOMA; MULTIPLE SCLEROSIS; NONHUMAN; PROSTATE CANCER; PROSTATITIS; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; URINARY FREQUENCY; UTERINE CERVIX CANCER; VACCINE PRODUCTION; VIRAL GENE DELIVERY SYSTEM; VIRUS LIKE AGENT; VOMITING;

ADJUVANTS, IMMUNOLOGIC; AUTOIMMUNE DISEASES; CANCER VACCINES; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; VACCINES;

EID: 80455123645     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2011.07.004     Document Type: Review

References (124)

1. McGraw-Hill concise dictionary of modern medicine 2002, The McGraw-Hill Companies, Inc.
2. Mandell: Mandell, Douglas, and Bennett's. Immunomodulators. Principles and practice of infectious diseases. 7th edition. 2009. p. 611-23. Chapter 42.
3. The American heritage dictionary of the English language 2009, Houghton Mifflin Company.
4. Sylvester R.J. Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer. Int J Urol 2011, 18:113-120.
5. Balwit J.M., Hwu P., Urba W.J., et al. The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program. J Transl Med 2011, 9(18):1-14.
6. Ochsenbein A.F., Klenerman P., Karrer U., et al. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci U S A 1999, 96(5):2233-2238.
7. Plotkin S, Orenstein W, Offit P. Noninfectious disease vaccines. Vaccines: expert consult. 5th edition. 2008. p. 1275-81. Chapter 53.
8. Plotkin S, Orenstein W, Offit P. Immunologic adjuvants. Vaccines: expert consult. 5th edition. 2008. p. 59-71. Chapter 5.
9. Tagliabue A., Rappuoli R. Vaccine adjuvants: the dream becomes real. Hum Vaccin 2008, 4(5):347-349. Landes Bioscience Journal.
10. HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 2002, 31(20):S34-S39.
11. Brunner R., Jensen-Jarolim E., Pali-Schöll I. The ABC of clinical and experimental adjuvants-a brief overview. Immunol Lett 2010, 121(1):29-35.
12. Billiau A., Matthys P. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J Leukoc Biol 2001, 70:849-860.
13. Stills H.F. Adjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvants. ILAR J 2005, 46(3):280-293.
14. Rajput Z.I., Hu S., Xiao C., et al. Adjuvants effects of saponins on animal immune responses. J Zhejiang Univ Sci B 2007, 8(3):153-161.
15. Roitt IM, Delves PJ, Martin SJ, et al. Innate immunity. Roitt's essential immunology. 11th edition. 2006. p. 1-20. Chapter 1.
16. Wheeler A.W., Marshall J.S., Ulrich J.T. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int Arch Allergy Immunol 2001, 126(2):135-139.
17. Dubensky T.W., Reed S.G. Adjuvants for cancer vaccines. Semin Immunol 2010, 22(3):155-161.
18. Baldridge J.R., Crane R.T. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods 1999, 19(1):103-107.
19. Cluff C.W. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol 2009, 667:111-123.
20. Suntharalingam G., Perry M.R., Ward S., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006, 355(10):1018-1028.
21. Xu J., Kochanek K.D., Murphy S.L., et al. Deaths: final data for 2007. Natl Vital Stat Rep 2010, 58(19):1-135.
22. Morales A., Eidinger D., Bruce A.W. Intracavitary Bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 1976, 116(2):180-183.
23. Aldrich J.F., Lowe D.B., Shearer M.H., et al. Vaccines and immunotherapeutics for the treatment of malignant disease. Clin Dev Immunol 2010, 2010:697158. 1-12.
24. Plotkin S, Orenstein W, Offit P. Therapeutic cancer vaccines. Vaccines: expert consult. 5th edition. 2008. p. 1136-45. Chapter 41.
25. Cheever M.A., Allison J.P., Ferris A.S., et al. The prioritization of cancer antigens: a National Cancer Institute Pilot Project for the Acceleration of Translational Research. Clin Cancer Res 2009, 15(17):5323-5337.
26. Bolhassani A., Safiyan S., Rafati S. Improvement of different vaccine delivery systems for cancer therapy. Mol Cancer 2011, 10(3):1-20.
27. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426.
28. Banchereau J., Briere F., Caux C., et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000, 18:767-811.
29. Palucka K., Ueno H., Banchereau J. Dendritic cells and immunity against cancer. J Intern Med 2011, 269:64-73.
30. O'Neill D.W., Adams S., Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004, 104:2235-2246.
31. Boudreau J.E., Bonehill A., Thielemans K., et al. Engineering dendritic cells to enhance cancer immunotherapy. Mol Ther 2011, 19(5):841-853.
32. Antonia S.J., Nirza N., Frickie I., et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006, 12(3):878-887.
33. Ridolfi R., Petrini M., Fiammenghi L., et al. Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients. J Transl Med 2006, 4(36):1-11.
34. Ridolfi L., Petrini M., Fiammenghi L., et al. Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis. Clin Dev Immunol 2010, 2010:504979. 1-9.
35. Carballido E., Fishman M., Sipuleucel T. Prototype for development of anti-tumor vaccines. Curr Oncol Rep 2011, 13:112-119.
36. Anderson R.J., Schneider J. Plasmid DNA and viral vector-based vaccines for the treatment of cancer. Vaccine 2007, 25(SUPPL 2):B24-B34.
37. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8):711-723.
38. Fioretti D., Iurescia S., Fazio V.M., et al. DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol 2010, 2010:174378. 1-16.
39. Webster R.G., Robinson H.L. DNA vaccines: a review of developments. BioDrugs 1997, 8(4):273-292.
40. Fissolo N., Montalban X., Comabella M. DNA-based vaccines for multiple sclerosis: current status and future directions. Clin Immunol 2010, [Epub ahead of print].
41. Wildbaum G., Youssef S., Karin N. A targeted DNA vaccine augments the natural immune response to self TNF-α and suppresses ongoing adjuvant arthritis. J Immunol 2000, 165:5860-5866.
42. DiPaola R.S., Plante M., Kaufman H., et al. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med 2006, 4:1.
43. Madan R.A., Arlen P.M., Mohebtash M., et al. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs 2009, 18(7):1001-1011.
44. Franz S.O., Downey S.G., Klapper J.A., et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008, 14(17):5610.
45. Hesseling AC, Behr MA. BCG: history, evolution, efficacy, and implications in the HIV era. Tuberculosis: a comprehensive clinical reference. Chapter 74. 2009.
46. Behr M.A. BCG-different strains, different vaccines?. Lancet Infect Dis 2002, 2:86-92.
47. Ritz N., Curtis N. Mapping the global use of different BCG vaccine strains. Tuberculosis 2009, 89(4):248-251.
48. Brewer T.F., Colditz G.A. Relationship between bacille Calmette-Guérin (BCG) strains and the efficacy of BCG vaccine in the prevention of tuberculosis. Clin Infect Dis 1995, 20(1):126-135.
49. CDC Division of Tuberculosis Elimination. BCG vaccine fact sheets. 2008. Available at: Accessed April 2011. http://www.cdc.gov/tb.
50. Comstock G.W. Snippets from the past: 70 years ago in the Journal. Am J Epidemiol 1999, 150(12):1263-1265.
51. Zbar B., Bernstein I.D., Rapp H.J. Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guérin. J Natl Cancer Inst 1971, 46(4):831-839.
52. Herr H.W., Morales A. History of bacillus Calmette-Guérin and bladder cancer: an immunotherapy success story. J Urol 2008, 179(1):53-56.
53. deKernion J.B., Golub S.H., Gupta R.K., et al. Successful transurethral intralesional BCG therapy of a bladder melanoma. Cancer 1975, 36(5):1662-1667.
54. Bloomberg S.D., Brosman S.A., Hausman M.S., et al. The effects of BCG on the dog bladder. Invest Urol 1975, 12(6):423-427.
55. Lamm D.L., Thor D.E., Harris S.C., et al. Bacillus Calmette-Guérin immunotherapy of superficial bladder cancer. J Urol 1980, 124(1):38-40.
56. Pinsky C.M., Camacho F.J., Kerr D., et al. Intravesical administration of bacillus Calmetter-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial. Cancer Treat Rep 1985, 69(1):47-53.
57. Wittes R.C. Immunology of bacille Calmette-Guérin and related topics. Clin Infect Dis 2000, 31(SUPPL 3):S59-S63.
58. Kumar M., Behera K., Matsuse H., et al. A recombinant BCG vaccine generates a Th1-like response and inhibits IgE synthesis in BALB/c mice. Immunology 1999, 97:515-521.
59. Kresowik T.P., Griffith T.S. Bacillus Calmette-Guérin immunotherapy for urothelial carcinoma of the bladder. Immunotherapy 2009, 1(2):281-288.
60. Roitt IM, Delves PJ, Martin SJ, et al. The production of effectors. Roitt's essential immunology. 11th edition. 2006. p. 185-210. Chapter 9.
61. Wiley S.R., Schooley K., Smolak P.J., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3(6):673-682.
62. Ludwig A.T., Morre J.M., Luo Y., et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for bacillus Calmette-Guérin-induced antitumor activity. Cancer Res 2004, 64:3386-3390.
63. Hall M.C., Chang S.S., Dalbagni G., et al. Guideline for the management of nonmuscle invasive bladder cancer: (stages Ta, T1, and Tis): 2007 update. J Urol 2007, 178(6):2314-2330.
64. Böhle A., Jocham D., Bock P.R. Intravesical bacillus Calmetter-Guérin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003, 169(1):90-95.
65. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000, 163(4):1124-1129.
66. Shelley M.D., Court J.B., Kynaston H., et al. Intravesical bacillus Calmette-Guérin in Ta and T1 bladder cancer. Cochrane Database Syst Rev 2000, 4. CD001986.
67. Lamm D.L. Efficacy and safety of bacilli Calmette-Guérin immunotherapy in superficial bladder cancer. Clin Infect Dis 2000, 31:S86-S90.
68. Nepple K.G., Lightfoot A.J., Rosevear H.M., et al. Bacillus Calmetter-Guérin with or without interferon a-2b and megadose versus recommended daily allowance vitamins during introduction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol 2010, 184(5):1915-1919.
69. Joudi F.N., Smith B.J., O'Donnell M.A., et al. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 2006, 24(4):344-348.
70. Morales A., Chin J.L., Ramsey E.W. Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. J Urol 2001, 166(5):1633-1637.
71. Morales A. Evolution of intravesical immunotherapy for bladder cancer: mycobacterial cell wall preparation as a promising agent. Expert Opin Investig Drugs 2008, 7(17):1067-1073.
72. Bastos R.G., Borsuk S., Seixas F.K., et al. Recombinant Mycobacterium bovis BCG. Vaccine 2009, 27:6495-6503.
73. Murray P.J., Aldovini A., Young R.A. Manipulation and potentiation of antimycobacterial immunity using recombinant bacilli Calmette-Guérin strains that secrete cytokines. Proc Natl Acad Sci U S A 1996, 93:934-939.
74. Yuan S., Shi C., Liu L., et al. MUC1-based recombinant bacillus Calmette-Guérin vaccines as candidates for breast cancer immunotherapy. Expert Opin Biol Ther 2010, 10(7):1037-1048.
75. Yuan S., Shi C., Ling R., et al. Immunization with two recombinant bacillus Calmette-Guérin vaccines that combine the expression of multiple tandem repeats of mucin-1 and colony stimulating-factor suppress breast tumor growth in mice. J Cancer Res Clin Oncol 2010, 136:1359-1367.
76. Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363(5):411-422.
77. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine-Denreon. Drugs R D 2006, 7(3):197-201.
78. Cheever M.A., Higano C. PROVENGE (Sipuleucel-T) in prostate cancer: the First FDA approved therapeutic cancer vaccine. Clin Cancer Res 2011, 17(11):3520-3526.
79. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004, 4(12):941-952.
80. Higano C., Schellhammer P.F., Small E.J., et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115(16):3670-3679.
81. Kantoff P.W., Schuetz T.J., Blumenstein B.A., et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010, 28(7):1099-1105.
82. Kunz M., Ibrahim S.M. Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity. Mediators Inflamm 2009, 2009:979258.
83. Delavallee L., Assier E., Denys A., et al. Vaccination with cytokines in autoimmune diseases. Ann Med 2008, 40(5):343-351.
84. Silva L.C., Ortigosa L.C., Benard G. Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy 2010, 2(6):817-833.
85. Delavallee L., Duvallet E., Semerano L., et al. Anti-cytokine vaccination in autoimmune diseases. Swiss Med Wkly 2010, 140:w13108.
86. Schur P. Overview of the systemic and nonarticular manifestations of rheumatoid arthritis. UpToDate 2011. Available at: Accessed April 2011. http://www.uptodate.com.
87. Stone JH. Overview of biological agents in the rheumatic diseases. UpToDate 2011. Available at: Accessed April 2011. http://www.uptodate.com.
88. Keffer J., Probert L., Cazlaris H., et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991, 10(13):4025-4031.
89. Dalum I., Butler D.M., Jensen M.R., et al. Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotechnol 1999, 17(7):666-669.
90. Bizzini B., Achour A. " Kinoids" the basis for anticytokine immunization and their use in HIV infection. Cell Mol Biol (Noisy-le-grand) 1995, 41(3):351-356.
91. Le Buanec H., Delavallee L., Bessis N., et al. TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc Natl Acad Sci U S A 2006, 103(51):19442-19447.
92. Delavallee L., Le Buanec H., Bessis N., et al. Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalpha. Ann Rheum Dis 2008, 67(9):1332-1338.
93. Delavallee L., Semerano L., Assier E. Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis. Arthritis Res Ther 2009, 11(6):R195.
94. Neovacs initiates a Phase II clinical study of its TNF-kinoid in Crohn's disease patients. Press release. Jan 2011. Available at: Accessed April 2011. http://www.neovacs.com.
95. Immunogenicity and safety of TNFa kinoid in rheumatoid arthritis with secondary resistance to TNFa antagonists and ADA. Ongoing Phase II trial. Available at: Accessed April 2011. http://clinicaltrials.gov/ct2/show/NCT01040715.
96. Spohn G., Keller I., Beck M., et al. Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur J Immunol 2008, 38(3):877-887.
97. Goldberg R., Zohar Y., Wildbaum G., et al. Suppression of ongoing experimental autoimmune encephalomyelitis by neutralizing the function of the p28 subunit of IL-27. J Immunol 2004, 173(10):6465-6471.
98. Bertin-Maghit S.M., Capini C.J., Bessis N. Improvement of collagen-induced arthritis by active immunization against murine IL-1beta peptides designed by molecular modelling. Vaccine 2005, 23(33):4228-4235.
99. Weiner H. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol 2004, 61(10):1613-1615.
100. Röhn T.A., Jennings G.T., Hernandez M. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol 2006, 36(11):2857-2867.
101. Uyttenhove C., Van Snick J. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur J Immunol 2006, 36(11):2868-2874.
102. Correale J., Farez M., Gilmore W. Vaccines for multiple sclerosis: progress to date. CNS Drugs 2008, 22(3):175-198.
103. Lublin F. History of modern multiple sclerosis therapy. J Neurol 2005, 252(SUPPL 3):iii3-iii9.
104. Vandenbark A.A., Morgan E., Bartholomew R., et al. TCR peptide therapy in human autoimmune diseases. Neurochem Res 2001, 26(6):713-730.
105. Vandenbark A.A., Culbertson N.E., Bartholomew R.M., et al. Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis. Immunology 2008, 123(1):66-78.
106. Kappos L., Comi G., Panitch H., et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat Med 2000, 6(10):1176-1182.
107. Wildbaum G., Karin N. Augmentation of natural immunity to a pro-inflammatory cytokine (TNF-alpha) by targeted DNA vaccine confers long-lasting resistance to experimental autoimmune encephalomyelitis. Gene Ther 1999, 6(6):1128-1138.
108. Youssef S., Wildbaum G., Maor G., et al. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. J Immunol 1998, 161(8):3870-3879.
109. Karpus W.J., Lukacs N.W., McRae B.L. An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol 1995, 155(10):5003-5010.
110. Roldão A., Mellado M.C., Castilho L.R., et al. Virus-like particles in vaccine development. Expert Rev Vaccines 2010, 9(10):1149-1176.
111. Deschuyteneer M., Elouahabi A., Plainchamp D., et al. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine. Hum Vaccin 2010, 6(5):407-419.
112. Brown M.J., Coltart J., Gunewardena K., et al. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond) 2004, 107(2):167-173.
113. Tissot A.C., Maurer P., Nussberger J., et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008, 371(9615):821-827.
114. Maurer P., Bachman M.F. Immunization against angiotensins for the treatment of hypertension. Clin Immunol 2010, 134(1):89-95.
115. Stoll G., Bendszus M. Inflammation and atherosclerosis. Novel insights into plaque formation and destabilization. Stroke 2006, 37:1923-1932.
116. Hauer A.D., van Puijvelde G.H., Peterse N., et al. Vaccination against VEGFR2 attenuates initiation and progression of atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27(9):2050-2057.
117. Petrovan R., Kaplan C.D., Reisfeld R.A., et al. DNA vaccination against VEGF receptor 2 reduces atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2007, 27(5):1095-1100.
118. Harrison L.C. The prospect of vaccination to prevent type I diabetes. Hum Vaccin 2005, 1(4):143-150.
119. Kimpimäki T., Kupila A., Hämäläinen A.M., et al. The first signs of beta-cell autoimmunity appear in infancy in genetically susceptible children from the general population: the Finnish Type 1 Diabetes Prediction and Prevention Study. J Clin Endocrinol Metab 2001, 86(10):4782-4788.
120. Harrison L.C., Honeyman M.C., Steele C.E., et al. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 2004, 27(10):2348-2355.
121. Plotkin S, Orenstein W, Offit P. Immunologic adjuvants. vaccines: expert consult. Chapter 1. 5th edition. 2008. p. 1-16.
122. Skyler J.S., Krischer J.P., Wolfsdorf J., et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention trial-type 1. Diabetes Care 2005, 28(5):1068-1076.
123. Näntö-Salonen K., Kupila A., Simell S., et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008, 372(9651):1746-1755.
124. Rewers M., Gottlieb P. Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future. Diabetes Care 2009, 32(10):1769-1782.